(PSTV) Plus Therapeutics - Ratings and Ratios

Plus Therapeutics, Inc. (NASDAQ:PSTV) is a clinical-stage pharmaceutical company specializing in the development of innovative cancer treatments. Its lead candidate, rhenium-186 (186Re) obisbemeda, is a patented radiotherapeutic agent designed to target central nervous system (CNS) cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microspheres, an intra-arterial treatment for solid organ cancers, such as primary and secondary liver cancers. Plus Therapeutics holds license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. Formerly known as Cytori Therapeutics, Inc., the company rebranded as Plus Therapeutics, Inc. in July 2019. Founded in 1996, it is headquartered in Austin, Texas.

The company’s focus on radiotherapeutics positions it in a niche segment of oncology, addressing unmet medical needs in challenging cancer types. Its pipeline leverages proprietary delivery mechanisms and radiopharmaceutical agents to target cancer cells while minimizing damage to healthy tissue. With a market capitalization of $8.49 million, the stock currently trades at $1.27, with a price-to-book ratio of 3.76, indicating a premium valuation relative to its book value. The company’s return on equity (RoE) stands at 249.03%, reflecting significant leverage in its financial structure. Plus Therapeutics continues to advance its clinical programs, with a focus on securing regulatory approvals and expanding its therapeutic portfolio.